Conference Coverage

2010 McDonald Criteria Are Effective for Early Diagnosis of Pediatric MS


 

AUSTIN—The 2010 Revised McDonald Diagnostic Criteria for Multiple Sclerosis (MS) may have a higher sensitivity for diagnosing pediatric MS, compared with the 2005 criteria. The revised criteria thus could allow for earlier initiation of disease-modifying therapy, researchers reported at the 2013 Annual Meeting of the Child Neurology Society.

Mitchel T. Williams, MD, Pediatric Neurologist at the Children’s Hospital of Michigan in Detroit, and colleagues conducted a retrospective study of 25 children who had been diagnosed with MS at the Children’s Hospital of Michigan from 2005 through early 2013. The researchers applied the 2005 and 2010 McDonald criteria based on neuroimaging findings and initial clinical presentation. The investigators also analyzed demographic data and compared those data with those of previous pediatric MS cohorts.

The median age at presentation, sex ratio, clinical symptoms, and relapse rate among the participants were comparable to those in previously published data, except for a high rate of African Americans (64%) among the 25 children. The researchers found that the initial MS diagnosis rate based on the 2005 McDonald criteria was 32%, compared with a rate of 92% using the 2010 McDonald criteria. The mean time after initial symptom presentation until the 2005 criteria for MS were met was 5.0 months, compared with 0.7 months for the 2010 McDonald criteria.

“[Our findings] suggest that the 2010 McDonald criteria are a more appropriate tool for the timely diagnosis of pediatric MS,” concluded the researchers.

Colby Stong
Editor

Recommended Reading

PML reported in multiple sclerosis patient on fingolimod
MDedge Neurology
How Effective Is Marijuana for MS?
MDedge Neurology
FDA Investigates Case of PML in Patient With MS Taking Fingolimod
MDedge Neurology
Brain Atrophy and Lesion Load Predict Long-Term Disability in Multiple Sclerosis
MDedge Neurology
Regulation May Be Impaired in Patients With Secondary Progressive MS
MDedge Neurology
Denmark Hosts the Premier International Meeting on MS
MDedge Neurology
Comparing Relapse Rates Among Patients With MS Who Switch From Interferon to Fingolimod or Glatiramer Acetate
MDedge Neurology
Anti-Lipid Oligoclonal IgM Bands Contribute to PML Risk Stratification
MDedge Neurology
Pre- and Post-Progression Relapses Impact Disability in Progressive MS
MDedge Neurology
Sodium Intake Is Associated With Increased Disease Activity in MS
MDedge Neurology